RecruitingNot ApplicableNCT05380531

Personalized Perioperative Analgesia Platform (PPAP) for Cesarean Section


Sponsor

Senthil Sadhasivam

Enrollment

600 participants

Start Date

Dec 5, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this collaborative CTSA (Clinical and Translational Science Award) application is to develop an innovative perioperative precision analgesia platform (PPAP) to improve analgesia and reduce serious immediate and long-term adverse outcomes of perioperative opioids in breastfeeding mothers and their infants


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria1

  • Adult women (\>18 yr) All races American Society of Anesthesiologists Classification (ASA) physical status: 1 to 3 undergoing elective Cesarean section that are willing to receive in-patient opioids.

Exclusion Criteria5

  • Health conditions including uncontrolled diabetes (gestational or pre-existing) or hypertension (pre-eclampsia, eclampsia, or chronic)
  • Any history of opioid misuse before or during pregnancy-per self-report and clinical notes
  • Preoperative severe pain and opioid use/misuse, allergy to oxycodone
  • Allergy to oxycodone
  • Significant neurological disorders, liver and renal diseases

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTPreoperative Genotyping

Genotype based risk prediction and personalized pain management


Locations(2)

UPMC Magee Women's Hospital

Pittsburgh, Pennsylvania, United States

University of Pittsburgh

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05380531


Related Trials